This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Detection of disease-associated α-synuclein in the cerebrospinal fluid: a feasibility study


Unterberger, Ursula, Lachmann, Ingolf, Voigtländer, Till, Pirker, Walter, Berghoff, Anna S., Flach, Katharina, Wagner, Uta, Geneste, Aline, Perret-Liaudet, Armand, Kovacs, Gabor G.


Clinical Neuropathology, Volume: 33, No.: 5, Pages.: 329-334

Year of Publication



With the aim to evaluate the significance and reliability of detecting disease-specific α-synuclein in the cerebrospinal fluid (CSF) we developed an ELISA and bead-assay. We used a commercial antibody (5G4) that does not bind to the physiological monomeric form of α-synuclein, but is highly specific for the disease-associated forms, including high molecular weight fraction of β-sheet rich oligomers. We applied both tests in CSF from a series of neuropathologically confirmed α-synucleinopathy cases, including Parkinson’ disease dementia (PDD) and dementia with Lewy bodies (DLB) (n = 7), as well as Alzheimer’ disease (n = 6), and control patients without neurodegenerative pathologies (n = 9). Disease-specific α-synuclein was detectable in the CSF in a subset of patients with α-synuclein pathology in the brain. When combined with the analysis of total α-synuclein, the bead-assay for disease-specific α-synuclein was highly specific for PDD/DLB. Detection of disease-associated αsynuclein combined with the total levels of α-synuclein is a promising tool for the in-vivo diagnosis of α-synucleinopathies, including PDD and LBD.;


adult, aged, aged, 80 and over, alzheimer disease, cerebrospinal fluid, diagnosi, diagnosis, feasibility studies, female, humans, immunomagnetic separation, lewy body disease, male, methods, middle aged, neurodegenerative diseases, parkinson disease, reproducibility of results, standards

Countries of Study


Types of Dementia

Alzheimer’s Disease, Lewy-Body, Parkinson’s Dementia

Types of Study

Case Control Study

Type of Outcomes


Type of Interventions

Diagnostic Target Identification

Diagnostic Targets

Biological Testing